Intravenous Lidocaine for Neuropathic Pain: A Retrospective Analysis of Tolerability and Efficacy
|
|
- Elfrieda Hunter
- 5 years ago
- Views:
Transcription
1 Pain Medicine 2014; 2015; : 16: Wiley Periodicals, Inc. NEUROPATHIC Intravenous Lidocaine PAIN SECTION for Neuropathic Pain: A Retrospective Analysis of Tolerability Brief and Efficacy Research Article Intravenous Lidocaine for Neuropathic Pain: A Retrospective Analysis of Tolerability and Efficacy Paul Hutson, PharmD,* Miroslav Backonja, MD, and Hanna Knurr, PharmD* *School of Pharmacy, University of Wisconsin, Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; CRILifetree Research, Salt Lake City, Utah, USA Reprint requests to: Paul Hutson, PharmD, School of Pharmacy, University of Wisconsin, 2220f Rennebohm Hall, 777 Highland Avenue, Madison, WI 53705, USA. Tel: (608) ; Fax: (608) ; paul.hutson@wisc.edu. Disclosure information: Paul Hutson has no potential conflicts to disclose. Miroslav Backonja has no potential conflicts to disclose. Hanna Knurr has no potential conflicts to disclose. Abstract Objectives. This study was designed to describe the efficacy and toxicity of intravenous (i.v.) lidocaine infusions for the treatment of neuropathic pain initially administered at a flat-rate trial dose of 500 mg over 30 minutes. Setting. Academic, tertiary care hospital and infusion center. Methods. Data were retrospectively collected and analyzed for efficacy, correlations between infusion rates with adverse effects, patterns of infusion rate adjustments, and infusion frequencies. Results. The average rate for all infusions was 9.1 mg/min. Efficacy was seen in 45 patients (65%), and all but eight patients (12%) required infusion rate reductions from the initial test rate of 16.7 mg/ min due to adverse effects. Fifty-five patients experienced adverse effects, with light-headedness as the most frequently reported side effect. Conclusion. The flat-dose trial used under the University of Wisconsin Health protocol for i.v. lidocaine administration did not cause serious adverse events, but few patients who responded to this trial dose tolerated subsequent infusions at the trial rate. Due to the lack of serious adverse events, administering an aggressive trial dose to elicit an analgesic response appears to be rational. If patients show a benefit from the trial dose, the need for reductions in infusion rate of subsequent doses should be anticipated. Key Words. Intravenous Lidocaine; Toxicity; Neuropathic Pain; Infusion Rate Background Chronic pain is a debilitating disorder that significantly decreases quality of life when inadequately managed. Neuropathic pain results from damaged or diseased nociceptive pathways of the nervous system and is characterized by spontaneous ongoing pain and by allodynia and hyperalgesia to various internal and external stimuli. There are various etiologies of neuropathic pain, and clinical manifestations are frequently variable in the scope and complex in presentation. A patient s response to therapy is unpredictable, and many patients struggle to achieve satisfactory pain relief and control in spite of modern pain management. Typically patients will trial regimens of opioids, antidepressants, and anticonvulsants in attempts to control neuropathic pain [1]. However, according to studies of neuropathic pain secondary to diabetic neuropathy and other etiologies when treated with drugs that relieve neuropathic pain, only 30% patients will achieve even partial relief of their pain symptoms with these medication regimens [2]. One of the proposed pathophysiological mechanisms that contribute to neuropathic pain is an upregulation of 5311
2 Hutson et al. sodium channels in nociceptors. The change in channel density on nociceptor membranes creates an electrochemical environment that causes neurons to reach their depolarization threshold more rapidly, which leads to increased nociceptive signaling. Lidocaine, a sodium channel blocker, may modulate neuropathic pain by decreasing the function of these sodium channels, reversing the effects of sodium channel upregulation [3]. Parenteral intravenous (i.v.) lidocaine administration for the off-label treatment of resistant neuropathic pain has been occurring in clinical practice since the 1950s [4]. Specifically, recent studies have found i.v. lidocaine therapy to be effective in treating neuropathic pain associated with spinal cord injury [5], diabetic neuropathy [2], central pain syndrome [6], chronic regional pain syndrome [7], and postherpetic neuralgia [8]. Additionally, i.v. lidocaine infusions have an opioid sparing effect during the postoperative period when administered during abdominal surgery [9]. The safety characteristics of i.v. lidocaine have been well established. The most common adverse effects seen with i.v. lidocaine include light-headedness, dizziness and confusion, lethargy, nausea and vomiting, vision changes, and perioral numbness [2 15]. Because of its antiarrhythmic effects, patients receiving lidocaine infusions are typically screened for conduction defects via electrocardiogram (ECG) prior to lidocaine administration. Patients at a heightened risk for arrhythmia should not receive lidocaine infusions. No studies have reported arrhythmias due to i.v. lidocaine for neuropathic pain. A statistically significant increase in mean blood pressure when compared with placebo [7,10] was the only reported cardiac effect. This result was reported in two studies as an increase of mm Hg in both mean systolic and mean diastolic blood pressure during or after lidocaine infusion. However, the duration of this elevation in blood pressure and its clinical significance was not reported. Although several studies have investigated i.v. lidocaine in neuropathic pain therapy, there is no consensus for dosing and administration of i.v. lidocaine. Some studies have found that the effect of lidocaine on neuropathic pain may be dose related [2,7,8,11]. There is currently no best practice or recommended guideline for the use of lidocaine infusions in this patient population. At the University of Wisconsin (UW) health infusion centers, a lidocaine infusion trial protocol has been in place for several years. All patients undergoing lidocaine infusion therapy for neuropathic pain are administered 500 mg lidocaine in 100 ml of normal saline over 30 minutes (16.7 mg/min) for their first infusion to establish whether the patient responds to and tolerates the treatment. This trial dose is higher and the duration of infusion is shorter than what is seen in most studies (Figures 1 and 2). Based upon the response of each patient to this test infusion, the patient and physician form a plan for future infusions (frequency, dose, and rate). The objective of this Number of infusions retrospective chart review was to assess the practice of a fixed trial dose protocol of more rapidly infused lidocaine. Methods A chart review of patients receiving i.v. lidocaine infusions for the indication of chronic neuropathic pain between January 2011 and December 2011 from any Health center was performed. Patients who received lidocaine for cardiac arrhythmias were excluded. Each eligible patient s lidocaine infusion history was analyzed retrospectively from their very first infusion to the most recent infusion. The UW Health Sciences Institutional Review Board approved this study. Per the UW lidocaine infusion protocol, patients with an established neuropathic pain diagnosis were screened with a 12-lead ECG for conduction abnormalities prior to beginning i.v. lidocaine therapy. An i.v. infusion of 500 mg lidocaine over 30 minutes was administered as the initial trial dose. All patients were observed closely, and a physician was immediately available over the 30-minute infusion. An observation period of 30 minutes was enforced Rate in mg/min Figure 1 Distribution of lidocaine infusion rates in the analyzed cohort. The initial trial infusion rate (solid black bar) is 16.7 mg/min. % of patients with AE Infusion rate (mg/min*kg) Figure 2 Cumulative percentage of patients who experienced an adverse effect at or below the indicated infusion rate. 2532
3 Parenteral Intravenous Lidocaine for Neuropathic Pain post infusion to assess adverse effects. Patients were educated on common lidocaine side effects, signs of a serious reaction, and instructed to rate their pain (pain severity scoring range of 1 to 10, with 10 being worst imaginable pain). Based upon patient response and tolerance of the trial infusion, the patient and physician chose to continue, discontinue, or adjust the dose and assign a frequency to the infusions. Data collected from each patient s medical record included dates of treatment, indication, type of infusion, dose, infusion time, adverse events, action taken as a result of an adverse event, duration of treatment, frequency of infusions, reason for discontinuation, pain scores, and vital signs that were taken preinfusion, during infusion, and postinfusion. Results A total of 69 patients who were administered i.v. lidocaine infusions at UW Health sites met inclusion criteria (Table 1). Data from 1,650 lidocaine infusions administered to these patients were analyzed. Only 262 (15.8%) of the infusion documentations included both pre- and postinfusion pain scores. The average change in 0 10 pain score was 3.6 out of 10 (standard deviation [SD] 1.7). IV Lidocaine Trial Fifty-eight of the 69 patients underwent their first dose at the institution s default dose of 500 mg infused over 30 minutes. Fifteen of the 58 did not tolerate the full trial infusion dose or required a rate reduction due to adverse events. Although the initial target dose was 500 mg, due to slowed or stopped lidocaine infusions, the actual dose administered averaged 364 mg (SD 78 mg), and the average infusion rate was 9.10 mg/min (SD 3.31 mg/min). Table 1 Patient demographics Treatment with Intermittent i.v. Lidocaine Infusions Only 23 (51%) of the 45 subjects continuing infusions remained at the trial infusion rate of 16.7 mg/min. Of those 23 subjects, only eight continued all subsequent infusions at this rate. Excluding each patient s initial trial infusion, 89% of infusion rates were between 4 and 14 mg/min (mean 9.1 mg/min). Dose reductions were required in 26 (57.8%), and rate reductions were required in 38 (82%) of the 45 patients that continued infusions after the first dose. The average interval at which patients received infusions was every 19.4 days. Only 38 (2.3%) of 1,650 infusions were stopped early or slowed due to adverse effects (Table 2). The average rate of these 38 infusions was 13.4 mg/min. Adverse effects occurred in 55 (79.9%) patients (average rate 13.2 mg/ min). Light-headedness was the most common adverse event, and all infusion-related toxicities were reversible. Compared with previous literature, adverse event incidence in patients receiving lidocaine at the trial rate (16.7 mg/min) was higher than the adverse event incidence in all but one other study. The average change from preinfusion to postinfusion vital signs were a slight drop in heart rate ( 3.8 bpm [SD 8.5]), systolic blood pressure ( 3.2 mm Hg [SD 21.2]), and diastolic blood pressure ( 0.6 mm Hg [SD 10.1]). Discussion The off-label use of lidocaine infusion for neuropathic pain is relatively uninvestigated, and it is difficult to discern the dose that will maximize patient analgesia while avoiding the risk of toxicity. This descriptive summary provides information about lidocaine dosing patterns in response to patient tolerance. Age (median and range) 57 years (12 91 years) Weight (average and range) 90.1 kg ( kg) Body surface area (Mosteller method) (average and range) 2.07 m 2 ( m 2 ) Body mass index (average and range) 32.0 ( ) Type of neuropathy Central pain syndrome 2 CRPS 24 Diabetic peripheral neuropathy 8 Fibromyalgia 3 Ischemic neuropathy 1 Malignant cancer pain 5 Median nerve neuropathy 1 Mononeuritis multiplex 1 Multiple sclerosis 2 Neuropathic pain (unspecified) 10 Postherpetic neuralgia 4 Poststroke pain 1 Posttraumatic or surgical pain 5 Sensory neuropathy 1 Trigeminal neuralgia 1 Patients without a specific diagnosis are categorized into the general category of Neuropathic Pain (unspecified). 5333
4 Hutson et al. Table 2 Adverse effects reported as the percentage of patients who experienced each side effect Side Effect Percentage of Patients Affected Average Infusion Rate at which Side Effect Occurred (mg/min) Total Arrhythmia 0 N/A Clumsiness/incoordination Confusion Delirium Dizziness/vertigo Headache Light-headedness Metallic taste Muscle twitching Nausea/vomiting Peri-oral numbness Peripheral numbness/dyesthesias Sedation/lethargy Speech disturbance Tingling Tinnitus Other Side effects were reported by the either the patient or the administering nurse. The average infusion rate of the infusion that the patient experienced the adverse effect is reported in mg/min. Efficacy Though there was a reduction in pain assessment scores, only 15% of infusions contained sufficient data to compare pre- and postinfusion pain score ratings. Additionally, many patients reported that the point at which they experienced maximal pain relief was 24 hours after the infusion was administered. Therefore, the efficacy of lidocaine infusions is arguably better reflected by the percentage of patients who continued therapy (indicating efficacy as well as tolerability of lidocaine infusions). The 1,579 of 1,650 infusions (95.7%) were repeat infusions for subjects, indicating that those who experienced benefit from the lidocaine infusions continued to see some effect, in some cases for 200 or more infusions. Most patients received subsequent infusions at lower rates than the trial rate, suggesting that efficacy was maintained for many patients even when doses are reduced. This also indicates that adverse effects occur at a higher frequency at higher infusion rates but can be effectively overcome by a decrease in infusion rate. Infusion Rate and Toxicity The distribution of lidocaine infusion rates (Figure 1) suggests that the most commonly tolerable, effective lidocaine infusion rate is between 4 and 12 mg/min. Only eight patients tolerated the trial infusion rate for all continued infusions, and no patients received an increase in dose or rate above the trial rate of 16.7 mg/min. The average rate of infusions that elicited an adverse event was reported was 13.1 mg/min (Table 3). The trial infusion rate for lidocaine described here is aggressive, and it is unlikely that most patients will tolerate repeated lidocaine infusions at 16.7 mg/min. However, the use of a high-dose trial infusion is an efficient way to determine whether a patient s neuropathic pain will respond to lidocaine. Additionally, toxicities at this and other infusion rates were not life threatening and quickly reversible. There was a single report of one subject that admitted to the emergency department as a result of an adverse effect mid-infusion in this review. However, this adverse effect (hypoglycemia) is not an adverse effect associated with lidocaine infusions and was considered circumstantial and not directly due to the infusion. There have been no side effects related to clinically apparent cardiac arrhythmias, indicating that these doses of infused lidocaine do not achieve levels in cardiac tissues high enough to cause cardiotoxic effects. However, patients at our institution are not monitored with telemetry during infusion. The most common side effects seen were transient light-headedness, dizziness/ vertigo, and clumsiness/incoordination. All of these resolved within the 30 minute postinfusion observation period. The decrease in mean blood pressure after lidocaine infusion was minimal and contrasts with a significant increase that was reported in two randomized controlled trials [7,10]. Comparison of Trial Infusions vs Maintenance Infusions The primary differences between initial trial infusions and subsequent maintenance infusions are the rate of infusion 4534
5 Parenteral Intravenous Lidocaine for Neuropathic Pain Table 3 Comparison of reports of Lidocaine for Treatment of Neuropathic Pain Study Patients (N) Study Type Lidocaine Dose(s) Infusion Duration Average Rate (mg/min/kg) UW Lidocaine trial dose 56 Retrospective chart review trial doses only UW Lidocaine all infusions 69 Retrospective chart review Varied. Mean: 364 mg Attal [6] 16 Randomized, double blind, placebo trial Attal [13] 22 Randomized, double blind, placebo trial Baranowski [8] 24 Randomized, double blind, placebo 500 mg 30 minutes Varied, Average: 45.1 minutes mg/kg 30 minutes mg/kg 30 minutes mg/kg 5 mg/kg Ivo [12] 31 Placebo controlled trial 6 mg/kg, 18 mg/kg 30 mg/kg 2 hours hours Bolus: 0.2 Infusion: 0.05 Dirks [5] 25 Placebo, 6.25 mg/kg 85 minutes: 2 mg/kg IV bolus over 10 minutes, followed by infusion 3 mg/kg/h for 85 minutes Finnerup [10] 24 Randomized, double blind, placebo 1 mg/kg 5 mg/kg Koppert [9] 12 Randomized, double blind, placebo 1.0 mg/kg injection and 1.5 mg/kg/h infusion Kvarnstrom [14] 12 Randomized, double blind, placebo Kvarnstrom [3] 10 Randomized, double blind, placebo 30 minutes Varied based on surgery time: started minutes before incision, ended 1 hour post op. Bolus: 0.1 Infusion: mg/kg 40 minutes: 1 mg/kg during 10minutes and then 1.5 mg/kg during 30 minutes 2.5 mg/kg 40 minutes: 1 mg/kg during 10 minutes and then 1.5 mg/kg during 30minutes Bolus: 0.1 Infusion: 0.05 Lidocaine infusion regimens and adverse effects of the UW Health s protocol for lidocaine when used for neuropathic pain are contrasted with the other reports of lidocaine infusion regimens and adverse effects. The UW infusions are reported both as total infusions and as a subgroup of the portion of infusions that were administered at the trial infusion rate. 5355
6 Hutson et al. and the incidence of adverse event. The average infusion rate of maintenance infusions was 8.8 mg/min, nearly a 50% reduction from the trial infusion rate. The rate of adverse effects per infusion in the maintenance infusions was 3.3% vs an incidence rate of 88% in the trial infusions. Though not all patients required rate reductions for maintenance infusions, the majority of patients continued their maintenance infusions at a reduced infusion rate and successfully decreased the incidence of adverse effects. The mean rate of all infusions in this retrospective review was 9.10 mg/min, which was higher than many rates seen in other lidocaine infusion studies (Table 3), and the trial infusion rate for first time lidocaine infusions (16.7 mg/min) was higher than rates used in all but one other study [5]. When the incidence of adverse event was correlated with average rate/kg bodyweight, lower rates of infusion were associated with lower side effect incidence across multiple studies (Figure 2). Another health center reported successful use of lidocaine for neuropathic pain using a trial infusion protocol followed by a continuous infusion. This institution used weight-based dosing to determine the initial trial infusion (1 3 mg/kg) over minutes or mg/kg/min to 0.15 mg/kg/min [15]. Thereafter, responders lidocaine infusion rates were titrated to the lowest rate that maintaining analgesic efficacy, typically around mg/kg/min mg/kg/min. Lidocaine serum levels were measured with results well below the toxic threshold of 6 μg/ml. Similarly, reversible adverse events of light-headedness and peri-oral numbness were anecdotally noted [15]. In conclusion, adverse effects occur more commonly at higher i.v. lidocaine infusion rates. The flat-dose trial used under the UW Health protocol for i.v. lidocaine administration did not cause serious adverse events, but few patients who responded to this trial dose tolerated subsequent infusions at the initial trial rate. Starting with an aggressive trial dose to elicit an analgesic response appears to be rational, given the lack of serious adverse events noted in this study and in other similar series of short lidocaine infusions. If patients show benefit from the trial dose, the need for reductions in infusion rate of subsequent doses should be anticipated. References 1 Dworkin RH, O Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85(suppl 3):S Wallace MS, Laitin S, Licht D, Yaksh TL. Concentration-effect relations for intravenous lidocaine infusions in human volunteers: Effects on acute sensory thresholds and capsaicin-evoked hyperpathia. Anesthesiology 1997;86: Kvarnström A, Karlsten R, Quiding H, Gordh T. The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand 2004;48: Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 2000;87: Tremont-Lukats IW, Hutson PR, Backonja MM. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin J Pain 2006;22: Attal N, Gaudé V, Brasseur L, et al. Intravenous lidocaine in central pain: A double-blind, placebocontrolled, psychophysical study. Neurology 2000; 54: Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. Concentration-effect relationship of intravenous lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology 2000; 92: Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage 1999;17: Koppert W, Weigand M, Neumann F, et al. Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg 2004;98: Finnerup NB, Biering-Sørensen F, Johannesen IL, et al. Intravenous lidocaine relieves spinal cord injury pain: A randomized controlled trial. Anesthesiology 2005;102: Viola V, Newnham HH, Simpson RW. Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006;20: Dirks J, Fabricius P, Petersen KL, Rowbotham MC, Dahl JB. The effect of systemic lidocaine on pain and secondary hyperalgesia associated with the heat/ capsaicin sensitization model in healthy volunteers. Anesth Analg 2000;91: Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62: Kvarnström A, Karlsten R, Quiding H, Emanuelsson BM, Gordh T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003;47: Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 2004;2:
Effective Date: 01/01/2012 Revision Date: Code(s): J2001 Injection, lidocaine HCl for intravenous infusion, 10 mg
ARBenefits Approval: 09/28/2011 Effective Date: 01/01/2012 Revision Date: Code(s): J2001 Injection, lidocaine HCl for intravenous infusion, 10 mg Medical Policy Title: Intravenous Lidocaine or Ketamine
More information9/18/2017. Pharmacology for Advanced Practice Nurses Annual Meeting of the Virginia Association of Clinical Nurse Specialists Richmond, VA
Pharmacology for Advanced Practice Nurses 2017 Annual Meeting of the Virginia Association of Clinical Nurse Specialists Richmond, VA Lidocaine and Ketamine in Pain Management Don H. Bivins, MD Director,
More information9/20/17. Disclosures. Objectives. Academy of Integrative Pain Management Annual Meeting 2017
Academy of Integrative Pain Management Annual Meeting 2017 Don H. Bivins, M.D. Carilion Clinic October 22, 2017 Disclosures I have no financial conflicts or disclosures to make. Objectives Converse knowledgeably
More informationIntravenous Anesthetics for the Treatment of Chronic Pain. Original Policy Date
MP 5.01.11 Intravenous Anesthetics for the Treatment of Chronic Pain Medical Policy Section Prescription Drugs Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationIntravenous lidocaine infusions. Dr Ian McConachie FRCA FRCPC
Intravenous lidocaine infusions Dr Ian McConachie FRCA FRCPC Thank the organisers for inviting me. No conflicts or disclosures Lidocaine 1 st amide local anesthetic Synthesized in 1943 by Lofgren in Sweden.
More informationName of Policy: Intravenous Anesthetics for the Treatment of Chronic Neuropathic Pain
Name of Policy: Intravenous Anesthetics for the Treatment of Chronic Neuropathic Pain Policy #: 446 Latest Review Date: September 2013 Category: Pharmacology Policy Grade: C Background/Definitions: As
More informationEffect of Intravenous Lidocaine on the Neuropathic Pain of Failed Back Surgery Syndrome
Original Article Korean J Pain 2012 April; Vol. 25, No. 2: 94-98 pissn 2005-9159 eissn 2093-0569 http://dx.doi.org/10.3344/kjp.2012.25.2.94 Effect of Intravenous Lidocaine on the Neuropathic Pain of Failed
More informationIntravenous Anesthetics for the Treatment of Chronic Pain
Intravenous Anesthetics for the Treatment of Chronic Pain Policy Number: 5.01.16 Last Review: 4/2017 Origination: 4/2009 Next Review: 4/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationPredictive Value of Lidocaine for Treatment Success of Oxcarbazepine in Patients with Neuropathic Pain Syndrome
Pain Ther (2013) 2:49 56 DOI 10.1007/s40122-013-0007-x ORIGINAL RESEARCH Predictive Value of Lidocaine for Treatment Success of Oxcarbazepine in Patients with Neuropathic Pain Syndrome Sivan Schipper Andreas
More informationNORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
NOVEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Sciatic Pain
More informationIntravenous Lidocaine for Neuropathic Pain: Diagnostic Utility and Therapeutic Efficacy
Intravenous Lidocaine for Neuropathic Pain: Diagnostic Utility and Therapeutic Efficacy Ian Carroll, MD, MS Corresponding author Ian Carroll, MD, MS Stanford University School of Medicine, 780 Welch Road,
More informationMr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government
Mr David A McDonald Service Improvement Manager Whole System patient Flow Improvement Programme Scottish Government Introduction Brief update Two main topics Use of Gabapentin Local Infiltration Analgesia
More informationThe Treatment of Chronic Pain by Infusion of IV Anesthetic and the Prevention of Phantom Limb Pain
The Treatment of Chronic Pain by Infusion of IV Anesthetic and the Prevention of Phantom Limb Pain Policy Number: 5.01.16 Last Review: 4/2014 Origination: 4/2009 Next Review: 4/2015 Policy Blue Cross and
More informationNeuropathic Pain in Palliative Care
Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic
More informationCorporate Medical Policy
Corporate Medical Policy Intravenous Anesthetics for the Treatment of Chronic Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intravenous_anesthetics_for_the_treatment_of_chronic_pain
More informationINTRAVENOUS LIDOCAINE INFUSIONS AND INTRALIPID RESCUE
INTRAVENOUS LIDOCAINE INFUSIONS AND INTRALIPID RESCUE Acute Pain Service-LHSC VH and UH sites HISTORY Lidocaine and procaine used by IV infusion in the 1950s and 1960s for general analgesia Often continued
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JUNE 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Acute Pain 2 Neuropathic
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationClinical Study The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial
ISRN Pain, Article ID 853826, 5 pages http://dx.doi.org/10.1155/2014/853826 Clinical Study The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial
More informationDose Response of Intrathecal Adenosine in Experimental Pain and Allodynia James C. Eisenach, M.D.,* Regina Curry, R.N., David D. Hood, M.D.
Anesthesiology 2002; 97:938 42 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Dose Response of Intrathecal Adenosine in Experimental Pain and Allodynia James C. Eisenach,
More informationOpioid reduction strategies in an academic tertiary medical center
Opioid reduction strategies in an academic tertiary medical center Terry Bosen, PharmD Medication Safety Program Director Vanderbilt University Medical Center Tennessee MME data per capita MME = Morphine
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationClinical Policy Title: Intravenous lidocaine infusion for neuropathic pain
Clinical Policy Title: Intravenous lidocaine infusion for neuropathic pain Clinical Policy Number: 03.03.08 Effective Date: June 1, 2014 Initial Review Date: January 19, 2014 Most Recent Review Date: January
More informationNEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES
NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.
More informationIt is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs.
Author query sheet Queries for Author Journal: Emergency Medicine Journal Paper: emermed-2014-203944 Title: Comparison of intravenous lidocaine versus morphine in alleviating pain in patients with critical
More informationClinical Trial Results Summary Study EN3409-BUP-305
Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin
More informationThe Effect of Intravenous Lidocaine on Post Herpetic Neuralgia in Palliative Care Unit: A Randomized Double Blind Placebo Controlled Trial
The Effect of Intravenous Lidocaine on Post Herpetic Neuralgia in Palliative Care Unit: A Randomized Double Blind Placebo Controlled Trial Jain R 1, Patel N.P. 2, Ratre B.K. 3 1 Dr Roopesh Jain, Professor
More informationOverview of Pain Types and Prevalence
Pain Resource Nurse Overview of Pain Types and Prevalence Pain Resource Nurse Program Module 1 The Resource Center of the Alliance of State Pain Initiatives University of Wisconsin Board of Regents, 2011
More informationINTERACTIVE QUESTIONS
INTERACTIVE QUESTIONS Pathophysiology What is pain? Pathophysiology Does everyone feel pain the same way? Pathophysiology From a practical point of view, how do you classify pain? Pathophysiology What
More informationEffects of gabapentin on morphine consumption and pain in severely burned patients
burns 33 (2007) 81 86 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/burns Effects of gabapentin on morphine consumption and pain in severely burned patients Olivier Cuignet
More informationManagement of Neuropathic pain
Management of Neuropathic pain Ravi Parekodi Consultant in Anaesthetics and Pain Management 08/04/2014 Ref: BJA July2013, Map of Medicine2013, Pain Physician 2007, IASP 2012, Nice guideline 2013 Aims Highlight
More informationNon-Opioid Pain Management: In the ED and Beyond
Non-Opioid Pain Management: In the ED and Beyond Craig P. Worby, PharmD BCCCP BCPS Clinical Lead Pharmacist Emergency Medicine Dartmouth Hitchcock Medical Center Objectives Describe the pathophysiology
More informationSufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type
Sufentanil Sublingual Tablet System 15mcg vs IV PCA Morphine: A Comparative Analysis of Patient Satisfaction and Drug Utilization by Surgery Type 2016 European Society of Regional Anesthesia Congress Maastricht,
More informationA Pain Management Primer for Pharmacists. Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE
A Pain Management Primer for Pharmacists Jessica Geiger-Hayes, PharmD, BCPS, CPE Andrea Wetshtein, PharmD, BCPS, CPE Objectives Discuss the differences between somatic, visceral, and neuropathic pain Design
More information16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces
16 year old with Disabling Chest Wall Pain after Thoracoscopic Talc Pleurodesis for Treatment of Recurrent Spontaneous Pneumothoraces Moderators: Kendra Grim, MD, Robert T. Wilder, MD, PhD Institution:
More informationAcute Pain NETP: SEPTEMBER 2013 COHORT
Acute Pain NETP: SEPTEMBER 2013 COHORT Pain & Suffering an unpleasant sensory & emotional experience associated with actual or potential tissue damage, or described in terms of such damage International
More informationMEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationA Gathering Storm: Evaluating Perioperative Opioids
A Gathering Storm: Evaluating Perioperative Opioids Michael Bottros, MD Disclosure Nothing to disclose 1 Objectives Describe the history of opioid prescribing practices in the United States Describe the
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationMedications for the Treatment of Neuropathic Pain
Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory
More informationEfficacy of Outpatient Ketamine Infusions in Refractory Chronic Pain Syndromes: A 5-Year Retrospective Analysispme_
Pain Medicine 2012; 13: 263 269 Wiley Periodicals, Inc. Efficacy of Outpatient Ketamine Infusions in Refractory Chronic Pain Syndromes: A 5-Year Retrospective Analysispme_1241 263..269 Sheetal Patil, MD,
More informationMorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients
Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationAnaesthesia and Pain Management for Endo Exo Femoral Prosthesis (EEFP) Bridging the Gap from Surgery to Rehabilitation
Anaesthesia and Pain Management for Endo Exo Femoral Prosthesis (EEFP) Bridging the Gap from Surgery to Rehabilitation Dr Ajay Kumar Senior Lecturer Macquarie and Melbourne University Introduction Amputee
More informationResults of a one-year, retrospective medication use evaluation. Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital
Results of a one-year, retrospective medication use evaluation Joseph Ladd, PharmD PGY-1 Pharmacy Resident BHSF Homestead Hospital Briefly review ketamine s history, mechanism of action, and unique properties
More informationPAIN TERMINOLOGY TABLE
PAIN TERMINOLOGY TABLE TERM DEFINITION HOW TO USE CLINICALLY Acute Pain Pain that is usually temporary and results from something specific, such as a surgery, an injury, or an infection Addiction A chronic
More informationPHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker
PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationA Gathering Storm: Evaluating Perioperative Opioids
A Gathering Storm: Evaluating Perioperative Opioids Michael Bottros, MD Disclosure Nothing to disclose 1 Learning Objectives Describe the history of opioid prescribing practices in the United States Describe
More informationSpinal Cord Injury Pain. Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018
Spinal Cord Injury Pain Michael Massey, DO CentraCare Health St Cloud, MN 11/07/2018 Objectives At the conclusion of this session, participants should be able to: 1. Understand the difference between nociceptive
More informationPeripheral neuropathy (PN)
Peripheral neuropathy (PN) damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic:
More informationAssay Sensitivity.
Assay Sensitivity Michael C. Rowbotham, MD Professor of Neurology UCSF-Mount Zion Pain Management Center Senior Scientist and IRB Chair, CPMC Research Institute Michael.Rowbotham@ucsf.edu Outline What
More informationHTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy
HTX-011, a Proprietary, Unique, Long-Acting Local Anesthetic, Reduces Acute Postoperative Pain Intensity and Opioid Consumption Following Bunionectomy Eugene Viscusi, 1 Oscar DeLeon-Casasola, 2 TJ Gan,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationDigital RIC. Rhode Island College. Linda M. Green Rhode Island College
Rhode Island College Digital Commons @ RIC Master's Theses, Dissertations, Graduate Research and Major Papers Overview Master's Theses, Dissertations, Graduate Research and Major Papers 1-1-2013 The Relationship
More informationCAESAREAN SECTION Brian Fredman
CHAPTER 3 GYNAECOLOGICAL SURGERY CAESAREAN SECTION Brian Fredman Review of evidence: surgical site infusion Of the seven studies on surgical site local anaesthetic infusion after Caesarean section performed
More informationContinuous Wound Infusion and Postoperative Pain Current status?
Continuous Wound Infusion and Postoperative Pain Current status? Pr Patricia Lavand homme Department of Anesthesiology St Luc Hospital University Catholic of Louvain Medical School Brussels, Belgium Severe
More information01/07/2018 ISCHAEMIC PAIN IN NON-RECONSTRUCTABLE CRITICAL LIMB ISCHAEMIA PRESENTATION OUTLINE
ISCHAEMIC PAIN IN NON-RECONSTRUCTABLE CRITICAL LIMB ISCHAEMIA Dr. Áine Ní Laoire The Oxford Advanced Pain & Symptom Management Course Nottingham 27 th June 2018 PRESENTATION OUTLINE A Typical Case Background
More informationGuidelines on the Safe Practice of Acute Pain Management
Page 1 of 7 Guidelines on the Safe Practice of Acute Pain Version Effective Date 1 1 MAY 1994 (Reviewed Feb 2002) 2 1 DEC 2014 Document No. HKCA P11 v2 Prepared by College Guidelines Committee Endorsed
More informationThe Emerging Role of NMDA Antagonists in Pain Management
1 of 5 5/29/16 5:18 PM www.medscape.com The Emerging Role of NMDA Antagonists in Pain Management Dana Jamero, PharmD, BCOP; Amne Borghol, PharmD; Nina Vo, PharmD Candidate; Fadi Hawawini, DO US Pharmacist
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationLidocaine inhibits neurite growth in mouse dorsal root ganglion cells in culture
Lidocaine inhibits neurite growth in mouse dorsal root ganglion cells in culture 3 Hiromi ~iruma', Hiroshi ~ aru~ama~, Zyun'ici B. Simada, Takashi Katakural, Sumio ~ oka~, Toshifumi ~akenaka~ and Tadashi
More informationLearning Objectives. Perioperative goals. Acute Pain in the Chronic Pain Patient for Ambulatory Surgery 9/8/16
Acute Pain in the Chronic Pain Patient for Ambulatory Surgery Danielle Ludwin, MD Associate Professor of Anesthesiology Division of Regional and Orthopedic Anesthesia Columbia University Medical Center
More informationPre-op Interventions to Mitigate Post-op Acute and Chronic Pain
Pre-op Interventions to Mitigate Post-op Acute and Chronic Pain H A R S H A S H A N T H A N N A. M D, M S C A S S O C I A T E P R O F E S S O R D E P A R T M E N T O F A N E S T H E S I A C H R O N I C
More informationSEEING KETAMINE IN A NEW LIGHT
SEEING KETAMINE IN A NEW LIGHT BobbieJean Sweitzer, M.D., FACP Professor of Anesthesiology Director of Perioperative Medicine Northwestern University Bobbie.Sweitzer@northwestern.edu LEARNING OBJECTIVES
More informationPrevention and Treatment Patrick Levelle, MD
Prevention and Treatment Patrick Levelle, MD LOCAL ANESTHETIC TOXICITY 1. PERIPHERAL NERVE BLOCKS 2. ROLE OF THE PERIANESTHESIA RN 3. LOCAL ANESTHETIC TOXICITY Use of Lipid Emulsion Regional and Peripheral
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress REDUCING THE PAIN FACTOR AN UPDATE ON PERI-OPERATIVE ANALGESIA Sandra Forysth, BVSc DipACVA Institute of Veterinary,
More informationCizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain
Cizolirtine Citrate (E-4018) in the Treatment of Chronic Neuropathic Pain P. Shembalkar 1, J. Täubel 2, M. Abadias 3, R. Arezina 2, K. Hammond 2 and P. Anand 1 Curr Med Res Opin 17(4):262-266, 2001. 2001
More informationPain: Current Understanding of Assessment, Management, and Treatments. Sponsored by the American Pain Sciety
Pain: Current Understanding of Assessment, Management, and Treatments Sponsored by the American Pain Sciety This program is supported by an unrestricted educational grant from NPC. For permission to reprint
More informationPAIN MEDICINE FOR THE NON-PAIN SPECIALIST 2017
PAIN MEDICINE FOR THE NON-PAIN SPECIALIST 2017 FEBRUARY 16-18, 2017 JW MARRIOTT DESERT SPRINGS RESORT & SPA PALM DESERT, CALIFORNIA Learn the latest treatment strategies and multidisciplinary management
More informationA randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in
A randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in patients using i.v. patient-controlled analgesia (PCA) for
More informationPeripheral Subcutaneous Field Stimulation
Peripheral Subcutaneous Field Stimulation Policy Number: 7.01.139 Last Review: 9/2014 Origination: 7/2013 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationNeuropathic pain (pain due to nerve damage)
Neuropathic pain (pain due to nerve damage) Clinical Guideline Pain can be nociceptive, neuropathic or mixed. The neuropathic component of pain generally responds poorly to conventional analgesics. Consider
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationGABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act
GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin
More informationGoals for sedation during mechanical ventilation
New Uses of Old Medications Gina Riggi, PharmD, BCCCP, BCPS Clinical Pharmacist Trauma ICU Jackson Memorial Hospital Disclosure I do not have anything to disclose Objectives Describe the use of ketamine
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Frequently Asked Questions: Table of Contents What clinical clues help distinguish between nociceptive and neuropathic pain? Can I combine treatments? Why should the treatment
More informationsensory nerves, motor nerves, autonomic nerves
damage or disease affecting nerves, which may impair sensation, movement, gland or organ function, or other aspects of health, depending on the type of nerve affected o chronic: long term, begins subtly
More informationEfficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L
Efficacy of postoperative epidural analgesia Block B M, Liu S S, Rowlingson A J, Cowan A R, Cowan J A, Wu C L CRD summary This review evaluated the efficacy of post-operative epidural analgesia. The authors
More informationOriginal Research Articles Efficacy of a Metered-dose 8% Lidocaine Pump Spray for Patients with Post-herpetic Neuralgiapme_
PAIN MEDICINE Volume 10 Number 5 2009 NEUROPATHIC PAIN SECTION Original Research Articles Efficacy of a Metered-dose 8% Lidocaine Pump Spray for Patients with Post-herpetic Neuralgiapme_662 902..909 Akifumi
More informationGabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement. Manyat Nantha-Aree, MD
Gabapentin Does Not Improve Analgesia Outcomes For Total Joint Replacement Manyat Nantha-Aree, MD Objective n Preliminary results of MOBILE study in total hip and knee arthroplasty Background n Gabapentin=
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: ABT-639 Name of Active Ingredient: ABT-639 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationObjectives 9/7/2012. Optimizing Analgesia to Enhance the Recovery After Surgery CME FACULTY DISCLOSURE
Optimizing Analgesia to Enhance the Recovery After Surgery Francesco Carli, M.D.. McGill University, Montreal, QC, Canada. ASPMN, Baltimore, 2012 CME FACULTY DISCLOSURE Francesco Carli has no affiliation
More informationGUIDELINES AND AUDIT IMPLEMENTATION NETWORK
GUIDELINES AND AUDIT IMPLEMENTATION NETWORK General Palliative Care Guidelines The Management of Pain at the End Of Life November 2010 Aim To provide a user friendly, evidence based guide for the management
More informationABSTRACT TITLE: Near-OR Perioperative Interventions to Decrease Hospital Length
ABSTRACT NUMBER: 020-0094 ABSTRACT TITLE: Near-OR Perioperative Interventions to Decrease Hospital Length of Stay AUTHORS: Mark J. Lenart, MD Vanderbilt University 1301 Medical Center Drive Nashville,
More informationWhat do we want for pain medications?
New Trends in Pain Pharmacotherapy Dr. Chi Wai Cheung MBBS(HK), FHKCA, FHKAM(Anaesthesiology), Dip Pain Mgt(HKCA) Clinical Assistant Professor Department of Anaesthesiology The University of Hong Kong
More informationIntravenous lidocaine for acute pain: an evidence-based clinical update
BJA Education, 16 (9): 292 298 (2016) doi: 10.1093/bjaed/mkw008 Advance Access Publication Date: 12 April 2016 Matrix reference 1D02, 2E01 Intravenous lidocaine for acute pain: an evidence-based clinical
More informationPain Management Clinic ISIC
Pain Management Clinic ISIC Let us rebuild a pain free life Pain is one of the commonest symptoms in patients attending OPDs of various hospitals and clinics. Chronic pain is any pain that has persisted
More informationMedical Policy Manual. Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April Section: Surgery Last Reviewed Date: April 2014
Medical Policy Manual Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April 2013 Section: Surgery Last Reviewed Date: April 2014 Policy No: 188 Effective Date: July 1, 2014 IMPORTANT REMINDER
More informationPeripheral Subcutaneous Field Stimulation. Description
Subject: Peripheral Subcutaneous Field Stimulation Page: 1 of 6 Last Review Status/Date: June 2016 Peripheral Subcutaneous Field Stimulation Description Peripheral subcutaneous field stimulation (PSFS,
More informationPFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium
PFIZER INC These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationProf Wayne Derman MBChB,BSc (Med)(Hons) PhD, FFIMS. Pain Management in the Elite Athlete: The 2017 IOC Consensus Statement
Prof Wayne Derman MBChB,BSc (Med)(Hons) PhD, FFIMS Pain Management in the Elite Athlete: The 2017 IOC Consensus Statement 2 as 20 Experts published and leaders in their respective field 12 month lead in
More informationCHAPTER 4 PAIN AND ITS MANAGEMENT
CHAPTER 4 PAIN AND ITS MANAGEMENT Pain Definition: An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. Types of Pain
More informationNational Institute for Health and Care Excellence. Neuropathic pain - pharmacological management Guideline consultation. Stakeholder Comments
National Institute for Health and Care Excellence Neuropathic pain - pharmacological management Guideline consultation Stakeholder Comments Please enter the name of your registered stakeholder organisation
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationWITH ISOBARIC BUPIVACAINE (5 MG/ML)
, 49, 2013, 3 63 (5 MG/ML) (5 MG/ML).,.,.,..,..,, SPINAL ANESTHESIA: COMPARISON OF ISOBARIC ROPIVACAINE (5 MG/ML) WITH ISOBARIC BUPIVACAINE (5 MG/ML) D. Tzoneva, Vl. Miladinov, Al. Todorov, M. P. Atanasova,
More informationAnesthesiology, V 92, No 1, Jan 2000
75 Anesthesiology 2000; 92:75 83 2000 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Concentration Effect Relationship of Intravenous Lidocaine on the Allodynia of Complex
More informationPOST-OP MULTIMODAL PAIN MANAGEMENT. Maripat Welz-Bosna Reading Hospital Medical Center Department of Medicine Hospitalist Services/Pain Management
POST-OP MULTIMODAL PAIN MANAGEMENT Maripat Welz-Bosna Reading Hospital Medical Center Department of Medicine Hospitalist Services/Pain Management Objectives Understand the basic neurobiology of the pain
More informationKayalvizhi 1, J. Radhika 1* Original Research Article. Abstract
Original Research Article Comparative evaluation of safety and efficacy of epidural bupivacaine with morphine and ketamine vs epidural bupivacaine with morphine alone for postoperative analgesia Kayalvizhi
More information